Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open Label, Multi-center Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology

NCT01672775 is registered in ClinicalTrials.gov with Agensys, Inc. as lead sponsor.

NCT NCT01672775
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01672775 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open Label, Multi-center Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology
Lead sponsor
Agensys, Inc.
Phase
Phase 1
Overall status
Completed
Start date
July 18, 2012
Completion date
February 21, 2017
Enrollment
34 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, renal cell, renal cell carcinoma of papillary histology, renal cell carcinoma with clear cell histology, renal cell carcinoma with non-clear cell histology